See more : Murphy Oil Corporation (MUR) Income Statement Analysis – Financial Results
Complete financial analysis of CardioGenics Holdings Inc (CGNH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CardioGenics Holdings Inc, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Autoliv, Inc. (ALIV-SDB.ST) Income Statement Analysis – Financial Results
- Liaoning Shidai Wanheng Co.,Ltd. (600241.SS) Income Statement Analysis – Financial Results
- M.D.C. Holdings, Inc. (MDC) Income Statement Analysis – Financial Results
- SolarBank Corporation (SUUN) Income Statement Analysis – Financial Results
- PT Diamond Citra Propertindo Tbk (DADA.JK) Income Statement Analysis – Financial Results
CardioGenics Holdings Inc (CGNH)
About CardioGenics Holdings Inc
CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.
| Metric | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.30K | 8.88K | 0.00 | 21.54K | 177.07K | 203.29K | 166.69K | 239.65K | 253.26K | 385.88K | 624.67K | 1.00M | 1.04M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 136.95K | 31.26K | 73.05K | 85.59K | 152.37K | 272.16K | 697.03K | 1.15M | 7.21M | 8.13M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 1.30K | 8.88K | 0.00 | -115.41K | 145.81K | 130.24K | 81.11K | 87.28K | -18.91K | -311.15K | -521.68K | -6.20M | -7.09M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | -535.80% | 82.35% | 64.07% | 48.66% | 36.42% | -7.46% | -80.63% | -83.51% | -619.46% | -680.44% |
| Research & Development | 215.79K | 500.94K | 419.36K | 522.95K | 613.50K | 692.04K | 1.57M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 541.59K | 451.47K | 1.89M | 741.96K | 1.35M | 1.16M | 1.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.55M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.87M |
| SG&A | 541.59K | 451.47K | 1.89M | 741.96K | 1.35M | 1.16M | 1.60M | 1.92M | 1.85M | 2.43M | 1.79M | 1.97M | 2.23M | 3.23M | 8.64M | 7.42M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 772.14K | 973.51K | 2.33M | 1.29M | 3.74M | 1.88M | 3.20M | 1.92M | 1.85M | 2.43M | 1.79M | 1.97M | 2.23M | 3.50M | 8.64M | 7.83M |
| Cost & Expenses | 772.14K | 973.51K | 2.33M | 1.29M | 3.74M | 1.88M | 3.34M | 1.95M | 1.92M | 2.51M | 1.94M | 2.24M | 2.93M | 4.64M | 15.85M | 15.96M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 0.00 | 3.49K | 0.00 | 0.00 | 13.22K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 300.12K | 21.67K | 20.14K | 0.00 | 0.00 | 1.66M | 0.00 | 513.98K | 0.00 | 23.93K | 0.00 | 3.60K | 1.53M | 0.00 |
| Depreciation & Amortization | 14.77K | 21.10K | 21.77K | 25.19K | 25.61K | 23.96K | 30.34K | 1.35M | 1.20M | 60.21K | 95.43K | 213.39K | 636.06K | 1.14M | 9.66M | 6.08M |
| EBITDA | -757.38K | -952.40K | -2.31M | -1.27M | -5.57M | -2.06M | -28.33M | -1.02M | -521.91K | -2.29M | -1.61M | -1.77M | -1.90M | -2.88M | -5.19M | -14.51M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -96,964.84% | -40,124.40% | 0.00% | 101,007.00% | -578.71% | 3,936.77% | -905.25% | -649.19% | -699.05% | -493.38% | -418.25% | -488.21% | -680.62% |
| Operating Income | -772.14K | -973.51K | -2.53M | -1.31M | -3.79M | -1.98M | -16.12M | -1.77M | -1.72M | -2.35M | -1.70M | -1.98M | -2.54M | -4.02M | -14.85M | -14.92M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -101,288.28% | -42,686.83% | 0.00% | -74,836.85% | -1,002.15% | -846.53% | -1,408.18% | -710.04% | -783.59% | -658.21% | -643.10% | -1,482.69% | -1,431.51% |
| Total Other Income/Expenses | -1.14M | -1.71M | -410.14K | -2.75K | -1.97M | -239.69K | -25.61M | -1.06M | -8.52M | -778.13K | -187.55K | -21.16K | 0.00 | -263.75K | -303.04K | -1.75M |
| Income Before Tax | -1.92M | -2.68M | -2.94M | -1.32M | -3.94M | -2.19M | -41.16M | -1.17M | -10.25M | -3.13M | -1.75M | -1.99M | 0.00 | -4.28M | -15.15M | -16.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -101,749.58% | -44,334.94% | 0.00% | -191,094.11% | -661.97% | -5,040.04% | -1,874.99% | -731.07% | -783.87% | 0.00% | -685.32% | -1,512.95% | -1,599.15% |
| Income Tax Expense | 1.14M | 1.71M | 281.83K | 19.25K | 141.04K | 147.77K | 25.61M | 1.06M | 10.05M | 1.29M | 187.55K | 21.16K | 38.82K | 3.60K | 1.82M | 1.75M |
| Net Income | -1.92M | -2.68M | -2.92M | -1.31M | -3.87M | -2.02M | -28.93M | -2.83M | -11.78M | -3.64M | -1.89M | -2.01M | -2.58M | -4.02M | -16.67M | -16.66M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -100,851.89% | -43,650.02% | 0.00% | -134,303.28% | -1,599.39% | -5,792.41% | -2,181.78% | -788.30% | -791.94% | -668.27% | -643.67% | -1,664.09% | -1,599.15% |
| EPS | -0.02 | -0.04 | -0.05 | -0.02 | -0.07 | -0.04 | -0.95 | -0.50 | -2.53 | -0.85 | -0.42 | -0.47 | -0.68 | -1.51 | -9.33 | -11.72 |
| EPS Diluted | -0.02 | -0.04 | -0.05 | -0.02 | -0.07 | -0.04 | -0.95 | -0.50 | -2.53 | -0.85 | -0.42 | -0.47 | -0.68 | -1.51 | -9.33 | -11.72 |
| Weighted Avg Shares Out | 94.42M | 61.70M | 57.17M | 55.63M | 54.17M | 49.62M | 30.39M | 5.69M | 4.65M | 4.29M | 4.45M | 4.27M | 3.77M | 2.66M | 1.79M | 1.42M |
| Weighted Avg Shares Out (Dil) | 94.42M | 61.70M | 57.17M | 55.63M | 54.17M | 49.62M | 30.39M | 5.69M | 4.65M | 4.29M | 4.45M | 4.27M | 3.77M | 2.66M | 1.79M | 1.42M |
Head-To-Head Contrast: CardioGenics (OTCMKTS:CGNH) versus Nielsen (OTCMKTS:NLSN)
Source: https://incomestatements.info
Category: Stock Reports